Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with

The safety and antiviral activity of the second-generation nonnucleoside inhibitor HBY 097 was investigated in asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-1-infected patients in a randomized, double-blinded, dose-escalation study. Mean maximum virus load decreases ranged fr...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1999-03, Vol.179 (3), p.709
Main Authors: Jorg-Peter Kleim, Winters, Mark, Dunkler, Anke, Jose-Ramon Suarez
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 709
container_title The Journal of infectious diseases
container_volume 179
creator Jorg-Peter Kleim
Winters, Mark
Dunkler, Anke
Jose-Ramon Suarez
description The safety and antiviral activity of the second-generation nonnucleoside inhibitor HBY 097 was investigated in asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-1-infected patients in a randomized, double-blinded, dose-escalation study. Mean maximum virus load decreases ranged from -1.31 log10 copies/mL of plasma at week 1 in the group receiving HBY 097 monotherapy (250 mg three times daily) to -2.19 log10 copies/mL at week 4 in the group receiving zidovudine plus HBY 097 (750 mg three times daily). After 12 weeks, these patients had viral RNA copy numbers 1.05 log10 below baseline. Genotypic analysis of resistance development revealed reverse transcriptase K103N variants in most patients, which was associated with less durable efficacy of HBY 097 treatment. Fewer patients receiving combination therapy with high-dose HBY 097 developed the K103N variant (P
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_223904709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39637443</sourcerecordid><originalsourceid>FETCH-proquest_journals_2239047093</originalsourceid><addsrcrecordid>eNqNikFOwzAQRS1EJULpHUbsIzlxSfASEKgHYMOqcp2JMlUyDva4KFfhtASJA7D67-u9K1VUD6Ytm6Yy16rQuq7L6tHaG3Wb0llrvTdNW6jvJxa6UHQjOP9LskDoQQaEIU-OgaYpc-iwJ0_IfoE1zglkmRGqMs3oaVXAgTn7EUOiDiHiBWNCkOg4-UizuPURD3QiCREOzx-gbQtuDIzguFsd-DCdiJ1QYPgiGe7Upndjwt3fbtX92-v7y6GcY_jMmOR4Djnyqo51bazet9qaf0U_4fZb3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223904709</pqid></control><display><type>article</type><title>Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Jorg-Peter Kleim ; Winters, Mark ; Dunkler, Anke ; Jose-Ramon Suarez</creator><creatorcontrib>Jorg-Peter Kleim ; Winters, Mark ; Dunkler, Anke ; Jose-Ramon Suarez</creatorcontrib><description>The safety and antiviral activity of the second-generation nonnucleoside inhibitor HBY 097 was investigated in asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-1-infected patients in a randomized, double-blinded, dose-escalation study. Mean maximum virus load decreases ranged from -1.31 log10 copies/mL of plasma at week 1 in the group receiving HBY 097 monotherapy (250 mg three times daily) to -2.19 log10 copies/mL at week 4 in the group receiving zidovudine plus HBY 097 (750 mg three times daily). After 12 weeks, these patients had viral RNA copy numbers 1.05 log10 below baseline. Genotypic analysis of resistance development revealed reverse transcriptase K103N variants in most patients, which was associated with less durable efficacy of HBY 097 treatment. Fewer patients receiving combination therapy with high-dose HBY 097 developed the K103N variant (P&lt;.01). HBY 097 caused pronounced acute suppression of HIV-1 replication both in combination with zidovudine and alone. Therefore, sustained antiviral activity can be expected from multiple combination therapy regimens including a quinoxaline derivative.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><ispartof>The Journal of infectious diseases, 1999-03, Vol.179 (3), p.709</ispartof><rights>Copyright University of Chicago, acting through its Press Mar 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Jorg-Peter Kleim</creatorcontrib><creatorcontrib>Winters, Mark</creatorcontrib><creatorcontrib>Dunkler, Anke</creatorcontrib><creatorcontrib>Jose-Ramon Suarez</creatorcontrib><title>Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with</title><title>The Journal of infectious diseases</title><description>The safety and antiviral activity of the second-generation nonnucleoside inhibitor HBY 097 was investigated in asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-1-infected patients in a randomized, double-blinded, dose-escalation study. Mean maximum virus load decreases ranged from -1.31 log10 copies/mL of plasma at week 1 in the group receiving HBY 097 monotherapy (250 mg three times daily) to -2.19 log10 copies/mL at week 4 in the group receiving zidovudine plus HBY 097 (750 mg three times daily). After 12 weeks, these patients had viral RNA copy numbers 1.05 log10 below baseline. Genotypic analysis of resistance development revealed reverse transcriptase K103N variants in most patients, which was associated with less durable efficacy of HBY 097 treatment. Fewer patients receiving combination therapy with high-dose HBY 097 developed the K103N variant (P&lt;.01). HBY 097 caused pronounced acute suppression of HIV-1 replication both in combination with zidovudine and alone. Therefore, sustained antiviral activity can be expected from multiple combination therapy regimens including a quinoxaline derivative.</description><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqNikFOwzAQRS1EJULpHUbsIzlxSfASEKgHYMOqcp2JMlUyDva4KFfhtASJA7D67-u9K1VUD6Ytm6Yy16rQuq7L6tHaG3Wb0llrvTdNW6jvJxa6UHQjOP9LskDoQQaEIU-OgaYpc-iwJ0_IfoE1zglkmRGqMs3oaVXAgTn7EUOiDiHiBWNCkOg4-UizuPURD3QiCREOzx-gbQtuDIzguFsd-DCdiJ1QYPgiGe7Upndjwt3fbtX92-v7y6GcY_jMmOR4Djnyqo51bazet9qaf0U_4fZb3Q</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Jorg-Peter Kleim</creator><creator>Winters, Mark</creator><creator>Dunkler, Anke</creator><creator>Jose-Ramon Suarez</creator><general>Oxford University Press</general><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>19990301</creationdate><title>Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with</title><author>Jorg-Peter Kleim ; Winters, Mark ; Dunkler, Anke ; Jose-Ramon Suarez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2239047093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jorg-Peter Kleim</creatorcontrib><creatorcontrib>Winters, Mark</creatorcontrib><creatorcontrib>Dunkler, Anke</creatorcontrib><creatorcontrib>Jose-Ramon Suarez</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jorg-Peter Kleim</au><au>Winters, Mark</au><au>Dunkler, Anke</au><au>Jose-Ramon Suarez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with</atitle><jtitle>The Journal of infectious diseases</jtitle><date>1999-03-01</date><risdate>1999</risdate><volume>179</volume><issue>3</issue><spage>709</spage><pages>709-</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>The safety and antiviral activity of the second-generation nonnucleoside inhibitor HBY 097 was investigated in asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-1-infected patients in a randomized, double-blinded, dose-escalation study. Mean maximum virus load decreases ranged from -1.31 log10 copies/mL of plasma at week 1 in the group receiving HBY 097 monotherapy (250 mg three times daily) to -2.19 log10 copies/mL at week 4 in the group receiving zidovudine plus HBY 097 (750 mg three times daily). After 12 weeks, these patients had viral RNA copy numbers 1.05 log10 below baseline. Genotypic analysis of resistance development revealed reverse transcriptase K103N variants in most patients, which was associated with less durable efficacy of HBY 097 treatment. Fewer patients receiving combination therapy with high-dose HBY 097 developed the K103N variant (P&lt;.01). HBY 097 caused pronounced acute suppression of HIV-1 replication both in combination with zidovudine and alone. Therefore, sustained antiviral activity can be expected from multiple combination therapy regimens including a quinoxaline derivative.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub></addata></record>
fulltext fulltext
identifier ISSN: 0022-1899
ispartof The Journal of infectious diseases, 1999-03, Vol.179 (3), p.709
issn 0022-1899
1537-6613
language eng
recordid cdi_proquest_journals_223904709
source JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online
title Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A16%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiviral%20activity%20of%20the%20human%20immunodeficiency%20virus%20type%201-specific%20nonnucleoside%20reverse%20transcriptase%20inhibitor%20HBY%20097%20alone%20and%20in%20combination%20with&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Jorg-Peter%20Kleim&rft.date=1999-03-01&rft.volume=179&rft.issue=3&rft.spage=709&rft.pages=709-&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/&rft_dat=%3Cproquest%3E39637443%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_2239047093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=223904709&rft_id=info:pmid/&rfr_iscdi=true